Documentos de Académico
Documentos de Profesional
Documentos de Cultura
y tratamiento crónico en el
SCASEST
Síndrome coronario agudo
(sca) en urgencias
CONTENIDO
1. Introducción
2. Complicaciones mecánicas
3. Trastornos de ritmo
4. Complicaciones inflamatorias
5. Tratamiento crónico
6. Bibliografía
Complicaciones esperables y tratamiento crónico en el SCASEST | 3
Fármaco Indicación
• AAS (75-100 mg) de forma indefinida (recomendación IA).
Antiagregantes • Doble antiagregación: AAS + Ticagrelor ó Prasugrel (ó Clopidogrel si no
disponibilidad de los anteriores) durante 12 meses tras ICP si no existe
contraindicación (recomendación IA).
AVK ó ACODs asociado a doble antiagregación en pacientes con indicación de
anticoagulación permanente
Antagonista • FEVI < 40% + ICC o diabetes (que ya reciban BB y IECA/ARA II) (recomendación
Mineralocorticoide IB).
Tabla 1.
8. Lindahl B, Baron T, Erlinge D, Hadziosmanovic 17. Farooq V, van Kaveren D, Steyerberg E, et al.
N, Nordenskjöld A, Gard A, Jernberg T. Medical Anatomical and clinical characteristics to guide
Therapy for Secondary Prevention and Long-Term decision making between coronary artery bypass
Outcome in Patients With Myocardial Infarction With surgery and percutaneous coronary intervention for
Nonobstructive Coronary Artery Disease. Circulation. individual patients: development and validation of
2017;135(16):1481-1489 SYNTAX score II. The Lancet 2013; 381:639-650.
9. Roffi M, Patrono C, Collet JP, et al. 2015 ESC 18. Heran BS, Chen JM, Ebrahim S, et al. Exercise-based
Guidelines for the management of acute coronary cardiac rehabilitation for coronary heart disease.
syndromes in patients presenting without persistent Cochrane Database Syst Rev 2011;1:CD001800.
ST-segment elevation. European Heart Journal 19. Zinman B, Wanner C, Lachin J, et al. Empagliflozin,
2016:37:267–315. Cardiovascular Outcomes, and Mortality in Type 2
10. Sherwood M, Newbuy K. High-Sensitivity Troponin Diabetes. N Engl J Med 2015; 373:2117-2128.
Assays: Evidence, indications, and reasonable use. J 20. Ibanez B, James S, Agewall S, Antunes MJ, Bucciarelli-
Am Heart Assoc. 2014;3:e000403. Ducci C, Bueno H, Caforio ALP, Crea F, Goudevenos
11. Granger CB. Strategies of patient care in acute JA, Halvorsen S, Hindricks G, Kastrati A, Lenzen
coronary syndromes: rationale for the Global Registry MJ, Prescott E, Roffi M, Valgimigli M, Varenhorst
of Acute Coronary Events (GRACE) registry. Am J C, Vranckx P, Widimsky P; Group ESCSD. 2017 ESC
Cardiol 2000;86(Suppl):4M-9M Guidelines for the management of acute myocardial
12. Mehta SR, Granger CB, Boden WE, et al. Early versus infarction in patients presenting with ST-segment
delayed invasive inter- vention in acute coronary elevation: The Task Force for the management of
syndromes. N Engl J Med 2009;360:2165–2175. acute myocardial infarction in patients presenting
with ST-segment elevation of the European Society
13. Stub D, Smith K, Bernard S, Nehme Z, Stephenson
of Cardiology (ESC). Eur Heart J 2017; doi:10. 1093/
M, Bray JE, Cameron P, Barger B, Ellims AH, Taylor
eurheartj/ehx393.
AJ, Meredith IT, Kaye DM. Air versus oxygen in ST
segment elevation myocardial infarction. Circulation 21. Valgimigli M, Gagnor A, Calabro P, Frigoli E, Leonardi
2015;131(24):2143–2150. S, Zaro T, Rubartelli P, Briguori C, Ando G, Repetto
A, Limbruno U, Cortese B, Sganzerla P, Lupi A, Galli
14. Wiviott S, Branwald E, McCabe C, et al. Prasugrel
M, Colangelo S, Ierna S, Ausiello A, Presbitero P,
versus Clopidogrel in Patients with Acute Coronary
Sardella G, Varbella F, Esposito G, Santarelli A,
Syndromes. N Engl J Med 2007; 357:2001-2015.
Tresoldi S, Nazzaro M, Zingarelli A, de Cesare N,
15. Wallentin L, Becker R, Budaj A, et al. Ticagrelor Rigattieri S, Tosi P, Palmieri C, Brugaletta S, Rao SV,
versus Clopidogrel in Patients with Acute Coronary Heg D, Rothenbuhler M, Vranckx P, Juni P, MATRIX
Syndromes. N Engl J Med 2009; 361:1045-1057 Investigators. Radial versus femoral access in
16. Farkouh M, Domanski M, Sleeper N, et al. Strategies patients with acute coronary syndromes undergoing
for Multivessel Revascularization in Patients with invasive management: a randomised multicentre
Diabetes. N Engl J Med 2012; 367:2375-2384 trial. Lancet 2015;385(9986):2465–2476